The FDA approved the combination to treat pediatric patients 1 year of age and older who have low-grade glioma with a BRAF V600E mutation and require systemic therapy.
Artificial intelligence can predict survival in cancer patients using information from a patient’s initial consultation with an oncologist, a study suggests.
Adding interferon alfa to treatment with temozolomide and radiotherapy prolongs survival in patients with newly diagnosed, high grade glioma, a phase 3 trial suggests.
Research suggests hippocampal-sparing radiation may be feasible for pediatric patients with medulloblastoma because the risk of peri‐hippocampal recurrence is low.
Adding an autologous tumor lysate-loaded dendritic cell vaccine to standard care improves survival in patients with glioblastoma, a phase 3 study suggests.
Most recent phase 3 trials of patients with newly diagnosed glioblastoma have shown no significant improvement in overall survival with the experimental treatment.
Researchers say they have identified a molecular signature that can be used to predict outcomes of regorafenib treatment in patients with recurrent glioblastoma.